Sensors,
Journal Year:
2024,
Volume and Issue:
24(9), P. 2904 - 2904
Published: May 1, 2024
Demand
is
strong
for
sensitive,
reliable,
and
cost-effective
diagnostic
tools
cancer
detection.
Accordingly,
bead-based
biosensors
have
emerged
in
recent
years
as
promising
platforms
based
on
wide-ranging
biomarkers
owing
to
the
versatility,
high
sensitivity,
flexibility
perform
multiplexing
of
beads.
This
comprehensive
review
highlights
trends
innovations
development
cancer-biomarker
We
introduce
various
types
such
optical,
electrochemical,
magnetic
biosensors,
along
with
their
respective
advantages
limitations.
Moreover,
summarizes
latest
advancements,
including
fabrication
techniques,
signal-amplification
strategies,
integration
microfluidics
nanotechnology.
Additionally,
challenges
future
perspectives
field
detection
are
discussed.
Understanding
these
can
greatly
contribute
improvements
diagnostics,
thereby
facilitating
early
personalized
treatments.
Acta Pharmacologica Sinica,
Journal Year:
2023,
Volume and Issue:
44(9), P. 1879 - 1889
Published: April 13, 2023
Immune-checkpoint
inhibitors
show
promising
effects
in
the
treatment
of
multiple
tumor
types.
Biomarkers
are
biological
indicators
used
to
select
patients
for
a
systemic
anticancer
treatment,
but
there
only
few
clinically
useful
biomarkers
such
as
PD-L1
expression
and
mutational
burden,
which
can
be
predict
immunotherapy
response.
In
this
study,
we
established
database
consisting
both
gene
clinical
data
identify
response
anti-PD-1,
anti-PD-L1,
anti-CTLA-4
immunotherapies.
A
GEO
screening
was
executed
datasets
with
simultaneously
available
transcriptomic
regardless
cancer
type.
The
restricted
studies
involving
administration
anti-PD-1
(nivolumab,
pembrolizumab),
anti-PD-L1
(atezolizumab,
durvalumab)
or
(ipilimumab)
agents.
Receiver
operating
characteristic
(ROC)
analysis
Mann-Whitney
test
were
across
all
genes
features
related
therapy
consisted
1434
tissue
samples
from
19
esophageal,
gastric,
head
neck,
lung,
urothelial
cancers,
plus
melanoma.
strongest
druggable
candidates
linked
resistance
SPIN1
(AUC
=
0.682,
P
9.1E-12),
SRC
0.667,
5.9E-10),
SETD7
0.663,
1.0E-09),
FGFR3
0.657,
3.7E-09),
YAP1
0.655,
6.0E-09),
TEAD3
0.649,
4.1E-08)
BCL2
0.634,
9.7E-08).
cohort,
BLCAP
0.735,
2.1E-06)
most
candidate.
No
therapeutically
relevant
target
found
predictive
cohort.
group,
able
confirm
significant
correlation
survival
mismatch-repair
MLH1
MSH6.
web
platform
further
validation
new
biomarker
set
up
at
https://www.rocplot.com/immune
.
summary,
investigate
large
cohort
solid
samples.
Our
results
could
help
patient
cohorts
eligible
immunotherapy.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(13), P. 2478 - 2478
Published: July 7, 2024
The
rise
of
drug
resistance
in
cancer
cells
presents
a
formidable
challenge
modern
oncology,
necessitating
the
exploration
innovative
therapeutic
strategies.
This
review
investigates
latest
advancements
overcoming
mechanisms
employed
by
cells,
focusing
on
emerging
modalities.
intricate
molecular
insights
into
resistance,
including
genetic
mutations,
efflux
pumps,
altered
signaling
pathways,
and
microenvironmental
influences,
are
discussed.
Furthermore,
promising
avenues
offered
targeted
therapies,
combination
treatments,
immunotherapies,
precision
medicine
approaches
highlighted.
Specifically,
synergistic
effects
combining
traditional
cytotoxic
agents
with
molecularly
inhibitors
to
circumvent
pathways
examined.
Additionally,
evolving
landscape
immunotherapeutic
interventions,
immune
checkpoint
adoptive
cell
is
explored
terms
bolstering
anti-tumor
responses
evasion
mechanisms.
Moreover,
significance
biomarker-driven
strategies
for
predicting
monitoring
treatment
underscored,
thereby
optimizing
outcomes.
For
future
direction
paradigms,
current
focused
prevailing
challenges
improving
patient
outcomes,
through
an
integrative
analysis
these
Biosensors,
Journal Year:
2024,
Volume and Issue:
14(7), P. 356 - 356
Published: July 22, 2024
The
steady
progress
in
consumer
electronics,
together
with
improvement
microflow
techniques,
nanotechnology,
and
data
processing,
has
led
to
implementation
of
cost-effective,
user-friendly
portable
devices,
which
play
the
role
not
only
gadgets
but
also
diagnostic
tools.
Moreover,
numerous
smart
devices
monitor
patients'
health,
some
them
are
applied
point-of-care
(PoC)
tests
as
a
reliable
source
evaluation
patient's
condition.
Current
practices
still
based
on
laboratory
tests,
preceded
by
collection
biological
samples,
then
tested
clinical
conditions
trained
personnel
specialistic
equipment.
In
practice,
collecting
passive/active
physiological
behavioral
from
patients
real
time
feeding
artificial
intelligence
(AI)
models
can
significantly
improve
decision
process
regarding
diagnosis
treatment
procedures
via
omission
conventional
sampling
while
excluding
pathologists.
A
combination
novel
methods
digital
traditional
biomarker
detection
portable,
autonomous,
miniaturized
revolutionize
medical
diagnostics
coming
years.
This
article
focuses
comparison
modern
techniques
AI
machine
learning
(ML).
presented
technologies
will
bypass
laboratories
start
being
commercialized,
should
lead
or
substitution
current
Their
application
PoC
settings
technology
accessible
every
patient
appears
be
possibility.
Research
this
field
is
expected
intensify
Technological
advancements
sensors
biosensors
anticipated
enable
continuous
real-time
analysis
various
omics
fields,
fostering
early
disease
intervention
strategies.
integration
health
platforms
would
predictive
personalized
healthcare,
emphasizing
importance
interdisciplinary
collaboration
related
scientific
fields.
Abstract
TRIM
proteins
are
characterized
by
their
conserved
N-terminal
RING,
B-box,
and
coiled-coil
domains.
These
efficient
regulators
of
autophagy,
apoptosis,
innate
immune
responses
confer
immunity
against
viruses
bacteria.
TRIMs
function
as
receptors
or
scaffold
that
target
substrates
for
autophagy-mediated
degradation.
Most
interact
with
the
BECN1-ULK1
complex
to
form
TRIMosomes,
thereby
efficiently
targeting
autophagosomes.
They
regulate
functions
ATG
through
physical
interactions
ubiquitination.
affect
lipidation
MAP1LC3B1
MAP1LC3B2,
which
is
a
prerequisite
phagophore
autophagosome
formation.
In
addition,
they
MTOR
kinase
TFEB,
regulating
expression
genes.
apoptosis
crucial
cell
proliferation
tumor
Many
intrinsic
extrinsic
via
surface
TGFBR2,
TNFRSF1A,
FAS.
Mitochondria
modulate
anti-
proapoptotic
BCL2,
BAX,
BAK1,
CYCS.
use
multipronged
approach
apoptotic
pathways,
culminating
in
coordinated
activation
inhibition
initiator
executor
CASPs.
Furthermore,
can
have
dual
effect
determining
fate
therefore
cellular
homeostasis.
this
review,
we
discuss
mechanistic
insights
into
role
autophagy
be
used
better
understand
physiology.
findings
develop
therapeutic
interventions
prevent
treat
multiple
genetic
infectious
diseases.
Graphical
World Journal of Gastroenterology,
Journal Year:
2023,
Volume and Issue:
29(17), P. 2515 - 2533
Published: May 5, 2023
Gastric
cancer
(GC)
remains
a
leading
cause
of
cancer-related
death
worldwide.
Less
than
half
GC
cases
are
diagnosed
at
an
advanced
stage
due
to
its
lack
early
symptoms.
is
heterogeneous
disease
associated
with
number
genetic
and
somatic
mutations.
Early
detection
effective
monitoring
tumor
progression
essential
for
reducing
burden
mortality.
The
current
widespread
use
semi-invasive
endoscopic
methods
radiologic
approaches
has
increased
the
treatable
cancers:
However,
these
invasive,
costly,
time-consuming.
Thus,
novel
molecular
noninvasive
tests
that
detect
alterations
seem
be
more
sensitive
specific
compared
methods.
Recent
technological
advances
have
enabled
blood-based
biomarkers
could
used
as
diagnostic
indicators
postsurgical
minimal
residual
disease.
These
include
circulating
DNA,
RNA,
extracellular
vesicles,
proteins,
their
clinical
applications
currently
being
investigated.
identification
ideal
markers
high
sensitivity
specificity
would
improve
survival
rates
contribute
advancement
precision
medicine.
This
review
provides
overview
topics
regarding
novel,
recently
developed
GC.
Biosensors,
Journal Year:
2023,
Volume and Issue:
13(3), P. 398 - 398
Published: March 18, 2023
Cancer
is
one
of
the
major
public
health
issues
in
world.
It
has
become
second
leading
cause
death,
with
approximately
75%
cancer
deaths
transpiring
low-
or
middle-income
countries.
causes
a
heavy
global
economic
cost
estimated
at
more
than
trillion
dollars
per
year.
The
most
common
cancers
are
breast,
colon,
rectum,
prostate,
and
lung
cancers.
Many
these
can
be
treated
effectively
cured
if
detected
primary
stage.
Nowadays,
around
50%
late
stages,
to
serious
complications
death.
Early
diagnosis
diseases
substantially
increases
efficient
treatment
high
chances
survival.
Biosensors
potential
screening
methodologies
useful
early
biomarkers.
This
review
summarizes
recent
findings
about
novel
biomarkers
their
advantages
over
traditional
biomarkers,
biosensing
diagnostic
methods
for
them;
thus,
this
may
helpful
recognition
monitoring
response
various
human
Clinical and Translational Medicine,
Journal Year:
2023,
Volume and Issue:
13(9)
Published: Sept. 1, 2023
Abstract
Background
To
date,
standardising
clinical
predictive
biomarkers
for
assessing
the
response
to
immunotherapy
remains
challenging
due
variations
in
personal
genetic
signatures,
tumour
microenvironment
complexities
and
epigenetic
onco‐mechanisms.
Main
body
Early
monitoring
of
key
non‐coding
RNA
(ncRNA)
may
help
predicting
efficacy
cancer
come
up
with
standard
ncRNA
biomarkers.
For
instance,
reduced
miR‐125b‐5p
level
plasma
non‐small
cell
lung
patients
treated
anti‐PD‐1
predicts
a
positive
outcome.
The
miR‐153
colorectal
chimeric
antigen
receptor
T
lymphocyte
(CAR‐T)
therapy
indicate
activation
T‐cell
killing
activity.
miR‐148a‐3p
miR‐375
levels
forecast
favourable
responses
CAR‐T‐cell
B‐cell
acute
lymphoblastic
leukaemia.
In
GPC3
peptide
vaccine,
serum
miR‐1228‐5p,
miR‐193a‐5p
miR‐375‐3p
were
reported
as
good
improved
overall
survival.
Therefore,
there
is
critical
need
further
studies
elaborate
on
that
have
potential
predict
early
immunotherapy.
Conclusion
This
review
summarises
important
different
immunotherapeutic
modalities,
including
monoclonal
antibodies,
small
molecule
inhibitors,
vaccines
CAR‐T
cells.
addition,
concise
discussion
forthcoming
perspectives
provided,
outlining
technical
approaches
optimal
utilisation
immunomodulatory
tools
therapeutic
targets.
MedComm,
Journal Year:
2024,
Volume and Issue:
5(9)
Published: Sept. 1, 2024
Abstract
Cell
death
regulation
is
essential
for
tissue
homeostasis
and
its
dysregulation
often
underlies
cancer
development.
Understanding
the
different
pathways
of
cell
can
provide
novel
therapeutic
strategies
battling
cancer.
This
review
explores
several
key
mechanisms
apoptosis,
necroptosis,
autophagic
death,
ferroptosis,
pyroptosis.
The
research
gap
addressed
involves
a
thorough
analysis
how
these
be
precisely
targeted
therapy,
considering
tumor
heterogeneity
adaptation.
It
delves
into
genetic
epigenetic
factors
signaling
cascades
like
phosphatidylinositol
3‐kinase/protein
kinase
B/mammalian
target
rapamycin
(PI3K/AKT/mTOR)
mitogen‐activated
protein
kinase/extracellular
signal‐regulated
(MAPK/ERK)
pathways,
which
are
critical
death.
Additionally,
interaction
microenvironment
with
cells,
particularly
influence
hypoxia,
nutrient
deprivation,
immune
cellular
interactions,
explored.
Emphasizing
strategies,
this
highlights
emerging
modulators
inducers
such
as
B
lymphoma
2
(BCL2)
homology
domain
3
(BH3)
mimetics,
tumour
necrosis
factor‐related
apoptosis‐inducing
ligand
(TRAIL),
chloroquine,
innovative
approaches
to
induce
ferroptosis
provides
insights
therapy's
future
direction,
focusing
on
multifaceted
circumvent
drug
resistance.
examination
evolving
underlines
considerable
clinical
potential
continuous
necessity
in‐depth
exploration
within
scientific
domain.